The next few decades will likely see psychedelic treatments go from relative obscurity to playing center stage in the psychiatric space. After decades of prohibition, psychedelics are now emerging as a potential alternative to traditional mental health therapies amid a surge in psychedelic research.
Numerous studies have revealed that hallucinogenic drugs can deliver significant mental health benefits when paired with talk therapy. Psychedelics may finally allow people to gain long-term relief from conditions such as post-traumatic stress disorder and depression, which often fail to respond to conventional treatments.
Although a lot of psychedelic research has occurred in Western countries such as the United States, Canada and Australia, other nations aren’t being left behind. In the Middle East, an Israeli startup plans to begin testing a new psychedelic spray to treat PTSD. Over the last two years, the Israeli Defense Ministry has identified that at least 5,000 Israelis suffer from post-traumatic stress disorder. The mental health disorder tends to affect women more than men, and is especially prevalent among soldiers who see active combat.
Existing therapies for PTSD aren’t always effective, and they don’t work for everyone, necessitating the development of more efficient PTSD treatments. The recent surge in psychedelic research has revealed that hallucinogenics have plenty of potential as therapies for PTSD, especially when paired with psychotherapy.
Madrigal Mental Care Facility chief of the advisory board, clinical psychologist and PTSD specialist Or Doek explains that there is no treatment for the underlying cause of PTSD and current treatments, such as antidepressants, are just meant to alleviate the symptoms.
Psychedelics are becoming increasingly popular as they offer patients a chance to deal with the underlying trauma and traumatic memories that cause disruptive mental health symptoms. Doek says that psychedelics help patients reframe traumatic memories from traumatic events to sad events and remove their negative power.
Madrigal Mental Care Facility founder David Gabbay developed technology that facilitates the delivery of hallucinogenics into the brain in minute doses. He explains that the technology encloses a psychedelic molecule in a nanobiodegradable capsule, which is then suspended in a nasal spray. The minuscule dose and the quick-delivery system cause immediate effects without the “psychedelic trip,” allowing patients to reframe prior traumatic events without experiencing hallucinogenic effects.
According to Gabbay, Madrigal Mental Care Facility is researching the effects of psilocybin, ketamine and ecstasy on the brain. The facility expects to begin human trials of its psychedelic nasal spray by 2024.
With all the investment being injected into psychedelic research and product development by companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), it may not be long before different formulations are approved for use via various administration methods tailored for different groups of patients.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin…
There is a growing trend in which parents take tiny doses of psychedelics like LSD…
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to…
A new study has found that while all ethnic and racial groups can benefit from…
A new study that is yet to be peer-reviewed has found that rats given psilocybin…
The American embassy in Peru has warned Americans against taking traditional psychedelics like the ayahuasca…